The wearable baby monitor trusted by millions globally expands reach to three continents, including North America, Europe, and now Africa.
Dr. Gordon Ringold to advise on various strategies related to the development of the Company’s novel cancer treatment platform
BD Expands Peripheral Artery Disease Awareness Efforts with ‘Love Your Limbs’ Community Screening Initiative
Renowned leaders in neurology, movement disorders, and commercialization join to shape Celeste® market strategy
Generic Saxenda® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market.
Halia Therapeutics Published in Journey of Drug Targeting
The Company filed a substantial non-provisional PCT patent application seeking worldwide protection for its novel cancer treatment platform
Epic Ventures Gains $200M Fresh Capital
CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced the availability of generic dalfampridine extended release tablets. Dalfampridine is a potassium channel blocker indicated to improve walking in certain adult patients with multiple sclerosis (MS). Specific information about the use of dalfampridine can be found here. CivicaScript will […]
The groundbreaking care model expanded from 5 to 15+ clinic locations to achieve 15% patient penetration rate, exceeding national benchmarks SALT LAKE CITY, UT — August 12, 2025 – Huntsman Mental Health Institute at the University of Utah is celebrating the 10th anniversary of its groundbreaking Behavioral Health Integration (BHI) Program, which has transformed mental […]
SALT LAKE CITY, Utah, Aug. 15, 2025 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics innovator specializing in silicon nitride (Si₃N₄) for medical device applications, today issued a business update in connection with the filing of the Company’s Quarterly Report on Form 10-Q for the period ended June […]
The WRAP North America registry is a prospective, multicenter study designed to collect real-world safety and effectiveness data on the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE). The first WRAP North America patient was enrolled at Bluff City Vascular, an interventional nephrology and vascular access center in Memphis, TN. SOUTH JORDAN, Utah, Aug. 18, 2025 (GLOBE NEWSWIRE) — […]
Following a heart attack, fibrosis is the primary obstacle to recovery. Healthy heart muscle is replaced with non-functional scar tissue, which stiffens the heart wall and leads to chronic heart failure. While therapies have been investigated, cell-based therapies have failed to resolve this issue, as transplanted cells do not survive or engraft effectively in the […]
Certification underscores Owlet’s commitment to bringing medically-certified infant monitoring technology to every family across the globe. LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announces that Dream Sock™ has received official certification from Australia’s Therapeutic Goods Administration (TGA), meeting rigorous standards required for medical devices […]
Marcy-l’Étoile (France), August 18, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the addition of Anterior Nasal Swab (ANS) as a […]
IRVINE, Calif.–(BUSINESS WIRE)– Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement (“ASR”) to repurchase $500 million of Edwards’ common stock. With this transaction, Edwards has repurchased more than $800 million of shares in 2025. Under the terms of this ASR, Edwards will receive an initial delivery of approximately […]
WEST VALLEY CITY, Utah – Aug. 21, 2025 – Nusano, a physics company transforming the production of radioisotopes, today cut the ribbon on its 190,000-square-foot radioisotope production facility. The site will be capable of producing more than 40 different radioisotopes for use in cancer diagnostics and therapeutics, as well as industrial applications, such as long-lived […]
SALT LAKE CITY, Utah August 21, 2025 — Sethera Therapeutics today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of peer-reviewed results describing an enzymatic crosslinking platform that forges durable thioether “staples,” locking peptides into drug-like cyclic architectures. The platform works across a broad range of substrates, including sequences built entirely […]
Intermountain Health Announces New Children’s Health President and Expands Leadership Role for Hospital President to Build on Legacy of Pediatric Excellence
Bioseeker™ is the AI Discovery Engine Powering Seek Labs’ Mission to Outpace Disease with Faster, Smarter Global Health Solutions
Thin-wall design with superior insertion and unique sheath-securement solution to support successful radial access procedures and may aid in reducing arterial spasm and occlusion
James A. Bowman brings decades of experience launching disruptive surgical innovations.
Quansys Biosciences Launches Q-View™ Imager Plus: Delivering Reproducible, high-impact ELISA Data with Ease
Improving Women’s Health: MobileODT Joins Liger Medical
Utah Investment Firm Expands to Deliver Flexible Capital to Transformative Healthcare Companies
Accelerating Development of Therapeutics to Bolster Global Protein Supply Chains
Nestmedic Selects Curavit Clinical Research as U.S. CRO Partner for Pioneering Prenatal Monitoring Trial
Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions
BioSeeker™ Powers Development of a First-of-Its-Kind Programmable Therapeutic for Respiratory Syncytial Virus (RSV)
Canary Speech announces it has obtained HITRUST e1 Certification, reinforcing its commitment to cybersecurity related to its voice biomarker technology.
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
